Fundraising FoxAdjuvance Technologies
New York, US · Delaware corporation
Find your way into Adjuvance Technologies
Sign up to see every warm intro you have to Adjuvance Technologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adjuvance Technologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
CF
Christopher FrigonExecutive
JG
Jeffrey GardnerExecutive
TM
Tyler MartinExecutive
PL
Phil LivingstonNamed on SEC filing
Board
MG
Mary GinBoard director
JG
John GalloBoard director
GP
Gregory PolandBoard director
Reported raises · per SEC filings
Form D private placements$13.4M disclosed across 2 rounds · 2015–2019
▶$10.7MraisedNov 2019 · 28 investors · BiotechnologyRule 506(b)
▶$10.7MraisedNov 2019 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac ChengDirector
- Ken KelleyDirector
- Stephen DillyDirector
- J. Tyler MartinExecutive Officer, Director
- Offering amount
- $24.7M
- Amount sold
- $10.7M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedNov 2016 · 15 investors · BiotechnologyRule 506(b)
▶$2.7MraisedNov 2016 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher FrigonExecutive Officer
- Jeffrey GardnerExecutive Officer
- Mary GinDirector
- Gregory PolandDirector
- Tyler MartinExecutive Officer, Director
- Phil LivingstonDirector
- John GalloDirector
- Offering amount
- $7M
- Amount sold
- $2.7M
- Minimum investment
- $25K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $527.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $223K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- How much funding has Adjuvance Technologies raised?
- Adjuvance Technologies has disclosed $13.4M raised across 2 rounds.
- Where is Adjuvance Technologies headquartered?
- Adjuvance Technologies is headquartered in New York, US.